To cite this paper use one of the standards below:
Human Respiratory Syncytial Virus (hRSV) is one of the leading causes of acute respiratory tract infections, including bronchiolitis and pneumonia, particularly in newborns, young children, immunocompromised individuals, and older adults. Despite the availability of monoclonal antibodies targeting the viral fusion protein for prophylactic use, therapeutic options for hRSV infection remain limited, costly, and may be associated with adverse effects. Moreover, the emergence of viral resistance highlights the need for the development of novel antiviral strategies targeting different stages of the viral life cycle. In this context, proteins involved in viral replication represent promising targets for drug discovery. Among these proteins, M2-1 acts as the transcription antitermination factor of the viral polymerase complex, whereas the nucleoprotein N protects the viral genomic RNA by forming the nucleocapsid and serves as the template for viral replication and transcription. The biological functions of both proteins rely on highly specific interactions with viral RNA and the viral phosphoprotein (P), making them attractive molecular targets for the development of small-molecule inhibitors capable of disrupting essential protein–protein and protein–RNA interactions. This work aims to identify molecular fragments capable of binding to M2-1 and the N-terminal domain of N (N-NTD) through a fragment-based drug discovery (FBDD) approach. So far, recombinant M2-1 protein was expressed in Escherichia coli and purified by affinity chromatography to obtain samples suitable for structural and biophysical analyses. Fragment screening experiments using CSP, T2 relaxation, and WaterLOGSY NMR have been performed, and the resulting spectra are currently being analyzed. Following fragment screening, the most promising hits are further characterized by Saturation Transfer Difference (STD) and ¹H–¹⁵N HSQC NMR experiments, fluorescence spectroscopy, molecular docking, and molecular dynamics simulations to determine binding affinities, interaction sites, and binding modes. Overall, this study is expected to provide insights into the molecular recognition mechanisms of M2-1 and N-NTD, supporting the rational design of novel antiviral candidates targeting essential components of the hRSV replication machinery and contributing to the development of alternative therapeutic strategies against hRSV infection.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper